Small dense low-density lipoprotein in familial combined hyperlipidemia: Independent of metabolic syndrome and related to history of cardiovascular events

被引:18
作者
Pauciullo, Paolo [1 ]
Gentile, Marco [1 ]
Marotta, Gennaro [1 ]
Baiano, Angela [1 ]
Ubaldi, Stefania [1 ]
Jossa, Fabrizio [1 ]
Iannuzzo, Gabriella [1 ]
Faccenda, Fulvio [1 ]
Panico, Salvatore [1 ]
Rubba, Paolo [1 ]
机构
[1] Univ Naples Federico II, Dept Clin & Expt Med, Sch Med, Nuovo Policlin, I-80131 Naples, Italy
关键词
Familial combined hyperlipidemia; Small dense LDL; Metabolic syndrome; CORONARY-ARTERY-DISEASE; ISCHEMIC-HEART-DISEASE; LDL PARTICLE-SIZE; APOLIPOPROTEIN-B; RISK; MEN; MARKER; LIPIDS; LUNG;
D O I
10.1016/j.atherosclerosis.2008.07.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: It is unclear whether small dense low-density lipoprotein (sdLDL) are associated with familial combined hyperlipidemia (FCHL), independently of the metabolic syndrome (MS). It is also unclear whether sdLDL are related to history of cardiovascular (CVD) events in FCHL patients, independently of MS. Patients and methods: Serum levels of sdLDL, expressed as percentage of total LDL cholesterol (LDL score), were determined in 137 probands with FCHL and in 133 normolipidemic, normotensive, normoglycemic healthy subjects. Results: In binary logistic regression age- and gender-adjusted LDL score values above the 90th and 95th percentiles of the values in the control group (10.23 and 13.11%, respectively) were found to be significant predictors of FCHL status, independently of MS diagnosis (p = 0.007 and p < 0.0001, respectively). Values of the LDL score above the 90th and the 95th percentile of the control group resulted to be significantly related to FCHL status, even after adjustment for the components of MS (p = 0.006 and p = 0.001, respectively). Among FCHL patients. values of the LDL score above 95th percentile of the values in the control group were found to be significantly related to personal and/or family history of CVD events, independently of age, gender, total cholesterol, apolipoprotein (apo) B, and MS status (p = 0.016). The same significant relationship was found adjusting for all components of MS (p = 0.034). Conclusions: High concentrations of sdLDL are highly specific markers of FCHL, independently of concomitant MS. In FCHL patients high levels of sdLDL are related to history of CVD events, independently of MS, total cholesterol and apo B. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:320 / 324
页数:5
相关论文
共 50 条
  • [21] Predictive value of small dense low-density lipoprotein cholesterol for cardiovascular events in Chinese elder diabetes mellitus patients
    Xu, Li
    Chen, Xu
    Lu, Jingfen
    Xu, Yan
    Yang, Honglin
    Zhou, Xuewen
    Zhou, Jun
    Xu, Jianhong
    Shen, Hao
    DIABETOLOGY & METABOLIC SYNDROME, 2021, 13 (01)
  • [22] Special Article - Small dense low-density lipoprotein-cholesterol (sdLDL-C): Analysis, effects on cardiovascular endpoints and dietary strategies
    Santos, Heitor O.
    Earnest, Conrad P.
    Tinsley, Grant M.
    Izidoro, Luiz F. M.
    Macedo, Rodrigo C. O.
    PROGRESS IN CARDIOVASCULAR DISEASES, 2020, 63 (04) : 503 - 509
  • [23] Changes in Small Dense Low-Density Lipoprotein Levels Following Acute Coronary Syndrome
    Emadzadeh, Mahdi Reza
    Alavi, Maryam-Sadat
    Soukhtanloo, Mohammad
    Mohammadpour, Toktam
    Rahsepar, Amir Ali
    Tavallaie, Shima
    Khojasteh, Roshanak
    Paydar, Roghayeh
    Amini, Maral
    Parizadeh, Seyyed Mohammad Reza
    Akhlaghi, Saeed
    Ghayour-Mobarhan, Majid
    Ferns, Gordon A.
    ANGIOLOGY, 2013, 64 (03) : 216 - 222
  • [24] An equation for calculating small dense low-density lipoprotein cholesterol
    Han, Tianjiao
    Piao, Zhe
    Yu, Zhiguo
    Xu, Wanqi
    Cui, Xiaofeng
    LIPIDS IN HEALTH AND DISEASE, 2024, 23 (01)
  • [25] Small dense low-density lipoprotein particles: clinically relevant?
    Krauss, Ronald M.
    CURRENT OPINION IN LIPIDOLOGY, 2022, 33 (03) : 160 - 166
  • [26] Small dense low-density lipoprotein-lowering agents
    Alizadeh-Fanalou, Shahin
    Nazarizadeh, Ali
    Alian, Fatemeh
    Faraji, Parisa
    Sorori, Bahareh
    Khosravi, Mohsen
    BIOLOGICAL CHEMISTRY, 2020, 401 (10) : 1101 - 1121
  • [27] Correlations of Estimated Serum Small Dense Low-Density Lipoprotein and Isoprostane with Metabolic Syndrome Criteria between Metabolic Syndrome and Non-Metabolic Syndrome Subjects in Selangor
    Razali, N. A. A.
    Rahman, T. Abdul
    Ismail, Z.
    Kadir, S. H. Sheikh Abdul
    Razak, S. Abdul
    Shariff, R. E. Raja
    Shibraumalisi, N. A.
    IIUM MEDICAL JOURNAL MALAYSIA, 2023, 22 (03): : 114 - 123
  • [28] Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases
    Ivanova, Ekaterina A.
    Myasoedova, Veronika A.
    Melnichenko, Alexandra A.
    Grechko, Andrey V.
    Orekhov, Alexander N.
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2017, 2017
  • [29] Integrated Small Dense Low-density Lipoprotein Profile in Cardiovascular Disease and Cancer: A Longitudinal Study
    Notarnicola, Maria
    De Nunzio, Valentina
    Tutino, Valeria
    Veronese, Nicola
    Guerra, Vito
    Osella, Alberto R.
    Caruso, Maria Gabriella
    Giampiero, De Michele
    Anna, Mastrosimini
    Palma, Iacovazzi
    Marisa, Chiloiro
    Marisa, Noviello
    Osvaldo, Burattini
    Vittorio, Pugliese
    Caterina, Bonfiglio
    Annamaria, Cisternino
    Benedetta, D'Attoma
    ANTICANCER RESEARCH, 2019, 39 (11) : 6035 - 6039
  • [30] Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses
    Calabresi, L
    Donati, D
    Pazzucconi, F
    Sirtori, CR
    Franceschini, G
    ATHEROSCLEROSIS, 2000, 148 (02) : 387 - 396